Also known as: 4'-O-Tetrahydropyranyladriamycin; THP-Adriamycin
Pirarubicin is an anthracycline antineoplastic agent that is a semisynthetic derivative of doxorubicin. It intercalates into DNA and inhibits topoisomerase II, disrupting DNA replication and transcription. It shows comparable antitumor activity to doxorubicin with potentially reduced cardiotoxicity. Mediocon Inc manufactures Pirarubicin API at its GMP-certified facility in Aurangabad, Maharashtra, India.
| Parameter | Specification |
|---|---|
| CAS Number | 72490-01-8 |
| Molecular Formula | C32H35NO12 |
| Molecular Weight | 627.62 g/mol |
| Grade | IP / BP / USP |
| Category | Antineoplastic Agent (Anthracycline) |
| Appearance | Red to reddish-purple crystalline powder |
| Solubility | Freely soluble in water, sparingly soluble in ethanol, practically insoluble in ether |
| Assay | NLT 98.0% |
| Loss on Drying | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| Residue on Ignition | NMT 0.1% |
| Microbial Limits | Complies with pharmacopoeia |
| Identification | IR, HPLC Compliant |
| Batch No | PIR/24032026 |
| Mfg Date | MAR 2026 |
| Exp Date | FEB 2031 |
| Packing | 25 kg HDPE drums / as per requirement |
Mediocon Inc is a GMP-certified API manufacturer and bulk pharmaceutical ingredient supplier based in Aurangabad, Maharashtra, India. We specialise in supplying Pirarubicin — CAS 72490-01-8 (CAS 72490-01-8) and over 1,000 other Active Pharmaceutical Ingredients, excipients, herbal extracts, and nutraceutical ingredients to pharmaceutical manufacturers worldwide.
Our Pirarubicin — CAS 72490-01-8 is manufactured under strict quality management protocols compliant with WHO-GMP, ISO 9001:2015, and major pharmacopoeial standards (IP, BP, USP, EP). Every batch undergoes full analytical testing — identity (IR/HPLC), assay, related substances, residual solvents (ICH Q3C), heavy metals, and microbial limits — before release with a Certificate of Analysis.
Export Markets
Quality & Compliance